Cover Image

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Current clinical guidelines suggest that breast cancers with low hormone receptor expression (LowHR) in 1-10% of tumor cells should be regarded as hormone receptor positive. However, clinical data show that these patients have worse outcome compared to patients with hormone receptor expression above...

Full description

Saved in:
Bibliographic Details
Main Authors: Jurmeister, Philipp (Author) , Weber, Karsten (Author) , Villegas, Sonia (Author) , Karn, Thomas (Author) , Untch, Michael (Author) , Thieme, Anne (Author) , Müller, Volkmar (Author) , Taube, Eliane (Author) , Fasching, Peter (Author) , Schmitt, Wolfgang D. (Author) , Marmé, Frederik (Author) , Stickeler, Elmar (Author) , Sinn, Bruno V. (Author) , Jank, Paul (Author) , Schem, Christian (Author) , Klauschen, Frederick (Author) , Mackelenbergh, Marion Tina van (Author) , Denkert, Carsten (Author) , Loibl, Sibylle (Author) , Capper, David (Author)
Format: Article (Journal)
Language:English
Published: 03 October 2021
In: Clinical epigenetics
Year: 2021, Volume: 13, Pages: 1-10
ISSN:1868-7083
DOI:10.1186/s13148-021-01176-5
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13148-021-01176-5
Get full text
Author Notes:Philipp Jurmeister, Karsten Weber, Sonia Villegas, Thomas Karn, Michael Untch, Anne Thieme, Volkmar Müller, Eliane Taube, Peter Fasching, Wolfgang D. Schmitt, Frederik Marmé, Elmar Stickeler, Bruno V. Sinn, Paul Jank, Christian Schem, Frederick Klauschen, Marion van Mackelenbergh, Carsten Denkert, Sibylle Loibl and David Capper
Description
Summary:Current clinical guidelines suggest that breast cancers with low hormone receptor expression (LowHR) in 1-10% of tumor cells should be regarded as hormone receptor positive. However, clinical data show that these patients have worse outcome compared to patients with hormone receptor expression above 10%. We performed DNA methylation profiling on 23 LowHR breast cancer specimens, including 13 samples with HER2 amplification and compared our results with a reference breast cancer cohort from The Cancer Genome Atlas to clarify the status for this infrequent but important patient subgroup.
Item Description:Gesehen am 09.12.2021
Physical Description:Online Resource
ISSN:1868-7083
DOI:10.1186/s13148-021-01176-5

Similar Items